Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Targacept has initiated a Phase II clinical trial of AZD3480 in adults with attention deficit and hyperactivity disorder or ADHD.
Subscribe to our email newsletter
The primary objective of the double blind, placebo controlled, crossover trial is to assess the efficacy of two different dose strengths of AZD3480 in adult subjects diagnosed with ADHD. The crossover trial design provides for each subject to serve as its own control by receiving both dose strengths of AZD3480 as well as placebo, with the treatment periods separated by a washout period.
The trial, which is planned to enroll 24 subjects, is being conducted at Fletcher Allen Health Care, an affiliate of the University of Vermont College of Medicine.
Targacept and AstraZeneca are collaborating on the execution of the trial, with Targacept responsible for managing and funding the trial and AstraZeneca responsible for providing the clinical trial materials and communicating with regulatory authorities.
Donald deBethizy, president and CEO of Targacept, said: “We expect this well-designed pilot study to provide valuable insight that will facilitate future development planning.”